

GLAXOSMITHKLINE PLC
Form 6-K
May 01, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending May 2013

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc - Result of AGM

GlaxoSmithKline plc (GSK) announces that at its Annual General Meeting (AGM) today, all resolutions were passed by shareholders.

GlaxoSmithKline AGM Poll Results

The following table shows the votes cast for each resolution:

| Resolution | Total votes for* | % | Total votes against | % | Total votes cast | Votes withheld** |
|--|---------------------|-------|------------------------|------|---------------------|---------------------|
| 1 Adoption of Directors' Report and Financial Statements | 3,713,877,875 | 98.86 | 42,764,532 | 1.14 | 3,756,642,407 | 9,313,386 |
| 2 Approval of the Remuneration Report | 3,528,115,173 | 94.55 | 203,482,136 | 5.45 | 3,731,597,309 | 34,358,483 |
| 3 Election of Lynn Elsenhans | 3,753,666,422 | 99.90 | 3,577,765 | 0.10 | 3,757,244,187 | 8,711,607 |
| 4 Election of Jing Ulrich | 3,753,601,642 | 99.90 | 3,623,347 | 0.10 | 3,757,224,989 | 8,730,805 |
| 5 Election of Hans Wijers | 3,712,833,757 | 98.82 | 44,327,830 | 1.18 | 3,757,161,587 | 8,794,257 |
| 6 Re-election of Sir Christopher Gent | 3,679,075,355 | 97.92 | 78,304,492 | 2.08 | 3,757,379,847 | 8,575,946 |
| 7 Re-election of Sir Andrew Witty | 3,753,850,300 | 99.90 | 3,750,413 | 0.10 | 3,757,600,713 | 8,355,081 |
| 8 Re-election of Professor Sir Roy Anderson | 3,753,929,716 | 99.91 | 3,483,857 | 0.09 | 3,757,413,573 | 8,542,221 |
| 9 Re-election of Dr Stephanie Burns | 3,749,134,033 | 99.78 | 8,228,665 | 0.22 | 3,757,362,698 | 8,592,951 |
| 10 Re-election of Stacey Cartwright | 3,735,971,985 | 99.43 | 21,360,372 | 0.57 | 3,757,332,357 | 8,623,292 |
| 11 Re-election of Simon Dingemans | 3,749,800,702 | 99.80 | 7,359,374 | 0.20 | 3,757,160,076 | 8,795,718 |
| 12 Re-election of Judy Lewent | 3,746,232,485 | 99.71 | 11,060,403 | 0.29 | 3,757,292,888 | 8,662,906 |
| 13 Re-election of Sir Deryck Maughan | 3,748,191,348 | 99.76 | 9,051,199 | 0.24 | 3,757,242,547 | 8,713,247 |
| 14 | 3,754,111,479 | 99.92 | 3,157,370 | 0.08 | 3,757,268,849 | 8,686,945 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | |
|----|---|---------------|-------|-------------|------|---------------|------------|
| | Re-election of Dr Daniel Podolsky | | | | | | |
| 15 | Re-election of Dr Moncef Slaoui | 3,749,544,391 | 99.79 | 7,827,828 | 0.21 | 3,757,372,219 | 8,583,575 |
| 16 | Re-election of Tom de Swaan | 3,674,675,513 | 97.80 | 82,485,251 | 2.20 | 3,757,160,764 | 8,795,029 |
| 17 | Re-election of Sir Robert Wilson | 3,753,535,701 | 99.90 | 3,775,827 | 0.10 | 3,757,311,528 | 8,644,121 |
| 18 | Re-appointment of auditors | 3,666,492,716 | 99.23 | 28,325,186 | 0.77 | 3,694,817,902 | 71,137,746 |
| 19 | Remuneration of auditors | 3,704,254,541 | 99.35 | 24,310,742 | 0.65 | 3,728,565,283 | 37,390,510 |
| 20 | Authority for the company to make donations to political organisations and incur political expenditure | 3,659,392,600 | 97.82 | 81,529,557 | 2.18 | 3,740,922,157 | 25,033,636 |
| 21 | Authority to allot shares | 3,682,938,519 | 98.08 | 72,177,589 | 1.92 | 3,755,116,108 | 10,839,686 |
| 22 | Disapplication of pre-emption rights*** | 3,691,777,819 | 98.38 | 60,965,026 | 1.62 | 3,752,742,845 | 13,212,949 |
| 23 | Authority for the company to purchase its own shares*** | 3,708,862,005 | 98.71 | 48,366,624 | 1.29 | 3,757,228,629 | 8,727,165 |
| 24 | Exemption from statement of senior statutory auditor's name | 3,737,291,344 | 99.55 | 16,941,270 | 0.45 | 3,754,232,614 | 11,723,180 |
| 25 | Authorise reduced notice of a general meeting other than an AGM*** | 3,387,919,216 | 90.22 | 367,203,576 | 9.78 | 3,755,122,792 | 10,832,999 |

Notes:

* Includes discretionary votes.

** A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

*** Indicates Special Resolutions requiring a 75% majority.

Sir Crispin Davis did not stand for re-election as a Director, and has stepped down from the Board with effect from the conclusion of the AGM.

The following table provides further relevant information:

| | GlaxoSmithKline's Thirteenth AGM (2013) | GlaxoSmithKline's Twelfth AGM (2012) |
|---|---|--|
| Issued share capital (excluding Treasury Shares) | 4,922,724,518 | 5,046,404,827 |
| Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares) | 76.50% | 76.91% |
| Total shareholder population | 144,196 | 147,408 |
| Total number of proxies lodged | 8,931 | 9,717 |
| % of shareholders who lodged proxies | 6.19% | 6.59% |
| Number of shareholders, corporate representatives and proxies who attended the AGM | 442 | 426 |

V A Whyte
Company Secretary
1 May 2013

These results will shortly be available on the company's website at www.gsk.com.

GlaxoSmithKline

Enquiries:

| | | | |
|--------------------------------|--------------------|-----------------------|------------------|
| UK Media enquiries: | David Mawdsley | +44 (0) 20 8047 5502 | (London) |
| | David Daley | +44 (0) 20 8047 5502 | (London) |
| | Catherine Hartley | +44 (0) 20 8047 5502 | (London) |
| US Media enquiries: | Stephen Rea | +1 215 751 4394 | (Philadelphia) |
| | Kevin Colgan | +1 919 483 2933 | (North Carolina) |
| | Melinda Stubbee | +1 919 483 2510 | (North Carolina) |
| | Mary Anne Rhyne | +1 919 483 0492 | (North Carolina) |
| | Sarah Alspach | +1 202 715 1048 | (Washington, DC) |
| | Jennifer Armstrong | +1 215 751 5664 | (Philadelphia) |
| Analyst/Investor enquiries: | Ziba Shamsi | +44 (0) 20 8047 3289 | (London) |
| | Lucy Budd | + 44 (0) 20 8047 2248 | (London) |
| | Tom Curry | + 1 215 751 5419 | (Philadelphia) |
| | Gary Davies | + 44 (0) 20 8047 5503 | (London) |
| | James Dodwell | + 44 (0) 20 8047 2406 | (London) |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: May 01, 2013

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc